Health Canada is in the “final stages” of reviewing the vaccine candidate for AstraZeneca COVID-19. Currently, the agency is going back and forth with the business about what information the label will include. Due in part to the way the clinical trials were set up, the review of the vaccine has been more’ complicated’.
Prime Minister Justin Trudeau said the vaccine and other evaluations are being “working around the clock” by Health Canada officials. The vaccine is a two-dose vaccine that has been approved for use by several other nations, including Britain, Australia, and South Africa. If regulatory approval were granted, the third vaccine considered safe to be used in this country would be the Pfizer-BioNTech and Moderna vaccines. The Canadian Health Ministry is currently evaluating the safety and efficacy of the Johnson & Johnson and Novavax vaccine candidates.
Health Canada has been able to expedite the review process for vaccine submissions. An emergency order enables the agency to evaluate rolling data from pharmaceutical companies as it comes in. Up to 76 million doses of the Novavax vaccine and up to 20 million doses of the AstraZeneca vaccine have access to Canada. The aim of the federal government was to have any newly approved vaccines arrive as soon as possible.